Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

JUL 01, 2015 - TheStreet

A Must Read - Share

10 Worst Health Care Stocks in the S&P 500

NEW YORK (TheStreet) -- The red-hot health care sector was a great place to put your money in the first half of the year. With nearly a 9% return, it handily beat the market, which was up a meager 0.2% over the same period. Yet, not all stocks in the sector participated in the growth. Here are the 10 worst-performing ...

Tags: 10 Worst Health Care Stocks in the S&P 500,  Amgen Latest News

JUN 29, 2015 - TheStreet

A Must Read - Share

4 Surprising Stocks to Buy Soon, According to Smead Value Fund Manager

NEW YORK (TheStreet) -- Gannett spinoff TEGNA (TGNA) mixes car sales, the Internet and television. And it's perfect to park in your portfolio, said Bill Smead, fund manager for the Smead Value Fund.  "They own all of Cars.com and 46 network affiliate TV stations, so they are the advertising vehicle of choice for local auto dealers," said Smead at this year's ...

Tags: 4 Surprising Stocks to Buy Soon, According to Smead Value Fund Manager,  Amgen Latest News

JUN 27, 2015 - Benzinga

A Must Read - Share

Biotech Short-Sellers Prefer Amgen To Gilead Sciences

Some of the biggest swings in short interest among the leading biotechs and emerging pharmaceuticals between the May 29 and June 15 settlement dates happened to Amgen, Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ:

Tags: Biotech Short-Sellers Prefer Amgen To Gilead Sciences,  Amgen Latest News

JUN 25, 2015 - Zacks Investment Research

A Must Read - Share

JUN 22, 2015 - Zacks Investment Research

A Must Read - Share

Amgen Presents Interim Data on Migraine Drug AMG 334 - Analyst Blog

Amgen (AMGN) presented encouraging 52-week interim open-label extension phase II study data on its migraine candidate, AMG 334.

Tags: Amgen Presents Interim Data on Migraine Drug AMG 334 - Analyst Blog,  Amgen Latest News